United Therapeutics (UTHR) announced that the FDA has cleared its investigational new drug application to initiate a clinical study of the ...

UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...

Is United Therapeutics (UTHR) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this ...

Silver Spring, MD-based United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

These companies valuations have fluctuated since - Exelixis' is now valued at $10.65bn, Genmab, $13.7bn, Alnylam, $32.4bn, BioMarin, $11.7bn, and United Therapeutics, $16.1bn, while Sarepta's ...